BUND FINANCE

BUND FINANCE › Stocks › GILD

Gilead Sciences, Inc. (GILD)

NASDAQ · Stock price, chart and technical analysis

US$168.98-1.28 (-0.75%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$170.26
OpenUS$169.15
Day rangeUS$167.36 – US$170.63
52-week rangeUS$116.88 – US$176.58
Market capUS$209.59B
Volume4.82M
50-day averageUS$155.90
200-day averageUS$141.99
Beta0.37
Last dividend per shareUS$3.25

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$27.3BUS$27.3BUS$27.1BUS$28.8BUS$29.4B
Net incomeUS$6.2BUS$4.6BUS$5.7BUS$480.0MUS$8.5B
EPS (diluted)4.933.644.500.386.78
Gross margin75.8%79.3%76.0%78.3%78.8%
Operating margin36.3%26.9%28.1%5.8%34.0%
Net margin22.8%16.8%20.9%1.7%28.9%
Free cash flowUS$10.8BUS$8.3BUS$7.4BUS$10.3BUS$9.5B
Total debtUS$26.7BUS$25.2BUS$25.0BUS$26.7BUS$24.9B
CashUS$5.3BUS$5.4BUS$6.1BUS$10.0BUS$7.6B

Compound annual growth: revenue 1.9% · net income 8.1% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E—63.4x27.1x
EV / EBITDA177.5x15.6x16.5x
Operating margin37.8%—3.6%
Net margin-12.5%—-0.0%
Debt / equity2.95—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Gilead Sciences, Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEODaniel O'Day
Employees17,000
IPO date1992-01-22

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vo…

www.gilead.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice